Paola Angelini
A5102028467- Neuroblastoma Research and Treatments
- Glioma Diagnosis and Treatment
- Adrenal and Paraganglionic Tumors
- Neurofibromatosis and Schwannoma Cases
- Virus-based gene therapy research
- COVID-19 Clinical Research Studies
- Sarcoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Mycorrhizal Fungi and Plant Interactions
- Long-Term Effects of COVID-19
- SARS-CoV-2 and COVID-19 Research
- Cancer, Hypoxia, and Metabolism
- Congenital Heart Disease Studies
- Neonatal Health and Biochemistry
- Fungal Biology and Applications
- Veterinary Oncology Research
- Childhood Cancer Survivors' Quality of Life
- Neuroendocrine Tumor Research Advances
- Autoimmune Neurological Disorders and Treatments
- Renal and Vascular Pathologies
- Blood disorders and treatments
- Acute Lymphoblastic Leukemia research
- Intensive Care Unit Cognitive Disorders
- Cell death mechanisms and regulation
- Coronary Artery Anomalies
Royal Marsden NHS Foundation Trust
2019-2025
Royal Marsden Hospital
2018-2025
Institute of Cancer Research
2018-2024
National Health Service
2023-2024
Memorial Sloan Kettering Cancer Center
2024
Guy's and St Thomas' NHS Foundation Trust
2022
King's College London
2022
Kings Health Partners
2022
Evelina London Children's Healthcare
2022
University of Toronto
2014-2016
PURPOSE Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood. Despite aggressive therapy, 5-year survival rate for patients with metastatic or recurrent disease remains poor, and beyond PAX-FOXO1 fusion status, no genomic markers are available risk stratification. We present an international consortium study designed to determine incidence driver mutations their association clinical outcome. PATIENTS AND METHODS Tumor samples collected from enrolled on Children's Oncology...
To review a historical cohort of childhood ganglioneuroma (GN), the benign representative peripheral neuroblastic tumor (PNT) family.Of 2,286 PNTs enrolled between 1979 and 2005, 146 (6.4%) were registered as GN. Histological revision was carried out on 76 tumors. Diagnosis confirmed in 45, while 27 reclassified ganglioneuroblastoma intermixed (GNBI) four other PNT subtypes.GNs differed from for sex, age, site, stage, markers, scintigraphic results. Characteristics reviewed 70 nonreviewed...
BackgroundFor children with cancer, the clinical integration of precision medicine to enable predictive biomarker–based therapeutic stratification is urgently needed.MethodsWe have developed a hybrid-capture next-generation sequencing (NGS) panel, specifically designed detect genetic alterations in paediatric solid tumours, which gives reliable results from as little 50 ng DNA extracted formalin-fixed paraffin-embedded (FFPE) tissue. In this study, we offered an NGS reporting via molecular...
<div>Abstract<p>We profiled a large heterogeneous cohort of matched diagnostic relapse tumor tissue and paired plasma-derived cell-free DNA (cfDNA) from patients with relapsed progressive solid tumors childhood. Tissue cfDNA sequencing results were concordant, wider spectrum mutant alleles higher degree intratumor heterogeneity captured by the latter, if sufficient ctDNA was present. Serial identified putative drivers relapse, alterations in epigenetic being common feature. In...
<p>Proportion of patients with genetic aberrations.</p>
<p>Concordance between ctDNA and tissue copy number profiles.</p>
<p>Similarity matrix for TFBS sets.</p>
<p>Cohort-wide oncoplot for tissue vs cfDNA variants.</p>
<p>Fragmentomics reveals disease specific differential accessibility at transcription factor binding sites.</p>
<p>STRINGDB interaction networks of disease-specific fragmentomics clusters.</p>
<p>Primary vs. relapse copy number profiles.</p>
<p>Fragmentomics reveals disease specific differential accessibility at transcription factor binding sites.</p>
<p>Top relapse-specific copy number events.</p>
<p>Disease-specific diagnostic vs. relapse sequence variants.</p>
<p>Fraction of genome altered by disease group.</p>
<p>Disease-specific cfDNA vs. tissue sequence variants.</p>